LGC launches AccuPlex verification panel

AccuPlex SARS-CoV-2, Flu A/B and RSV Reference Material Kit is designed to measure day-to-day performance of the assay, providing both a positive and a negative reference solution

LGC’s SeraCare has expanded its SARS-CoV-2 portfolio to include products designed for use with multiplexed molecular assays that can detect SARS-CoV-2, influenza A/B and respiratory syncytial virus (RSV).

AccuPlex SARS-CoV-2, Flu A/B and RSV Verification Panel is optimised for assay verification at installation by documenting test performance along the assay’s range, enabling laboratories to establish lower limits of detection, perform assay comparisons, and evaluate staff proficiency.

Michael Sweatt, Executive Vice President, LGC Clinical Diagnostics Division, stated, “The upcoming flu season will present clinicians and laboratorians with diagnostic challenges, while we remain in the throes of the COVID-19 pandemic. Patients presenting with symptoms, common to both the flu and SARS-CoV-2 symptomatic infections, will need to be stratified in order to enact the appropriate treatment and containment strategy.

“Aligned with LGC’s corporate philosophy of ‘Science for a Safer World’, we strive to continuously improve and expand upon our ability to support global public health efforts by providing valuable tools such as these multiplexed quality solutions in response to the ever changing needs of infectious disease diagnostics.”

LGC SeraCare’s proprietary AccuPlex technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient, the company says. These materials serve as true, full-process controls that challenge the entire molecular test procedure, making them the preferred alternative to infectious materials.

Companies